A WORKFLOW DRIVEN PLATFORM SOLUTION FOR MAM-BASED CRTICAL QUALITY ATTRIBUTE MONITORING OF BIOTHERAPEUTICS IN PROCESS DEVELOPMENT AND QC

Significance of the Topic

Biotherapeutic products require detailed monitoring of peptide based quality attributes to ensure safety and efficacy. The integration of advanced LC-MS workflows supports rapid detection of modifications arising during development, manufacturing and stress testing.

Study Objectives and Overview

This study demonstrates a workflow driven LC MS platform for automated peptide attribute profiling and monitoring in biotherapeutic process development and quality control. The focus lies on combining peptide mapping and accurate mass screening to detect, quantify and track critical quality attributes of monoclonal antibodies under stress conditions.

Methodology and Instrumentation

A model monoclonal antibody underwent pH, heat and oxidative stress followed by reduction, alkylation, buffer exchange and tryptic digestion. Separation was achieved on a UPLC CSH C18 column at 60 °C with an 80 min gradient. Mass analysis used the BioAccord SmartMS enabled system operating in positive ESI mode over m/z 50 to 2000 with data dependent fragmentation.
Used Instrumentation

• BioAccord LC MS system
• UPLC CSH C18 column, 1.7 µm, 2.1 x 100 mm
• UNIFI Scientific Information platform v1.9.4

Key Results and Discussion

Peptide mapping enabled identification of sequence variants and post translational modifications through chromatographic separation and fragment ion analysis. Accurate mass screening provided relative quantification of native and modified peptides with built in limit checks and new peak detection. The approach demonstrated comparable modification profiling using MS only or MS with fragmentation. Automated comparison of stressed and control samples simplified interpretation of multiple attribute monitoring studies.

Benefits and Practical Applications

The integrated workflow delivers a compact benchtop solution suitable for GMP compliant laboratories. One button startup, intelligent diagnostics and automated calibration routines make it accessible to non MS experts. Biopharma organizations can apply the methods from discovery through release testing to accelerate product development and ensure data integrity.

Future Trends and Applications

Future developments may include expanded attribute libraries for diverse modalities, cloud based data sharing, machine learning for pattern recognition and higher throughput screening. Integration with orthogonal assays and real time in process monitoring are emerging directions.

Conclusion

The presented workflow driven platform combines peptide mapping and accurate mass screening in a user friendly LC MS environment. It offers robust detection, quantification and reporting of critical quality attributes for biotherapeutics across R D and QC settings.

Reference

Ranbaduge NS, Qing Y, Du M, Chen W A workflow driven platform solution for MAM based critical quality attribute monitoring of biotherapeutics in process development and QC Waters Corporation 2019.